Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues.
Radiolabeled alpha-melanocyte stimulating hormone (a-MSH) analogues have been used to define the expression, affinity and function of the melanocortin-1 receptor (MC1-R). The MC1-R is one of a family of five G-protein linker receptors, which is primarily involved in regulation of skin pigmentation. Over-expression of the MC1-R on melanoma tumor cells has made it an attractive target for the development of a-MSH peptide based imaging and therapeutic agents. Initially, the native a-MSH peptide was radiolabeled directly, but it suffered from low specific activity and poor stability. The addition of non-natural amino acids yielded a-MSH analogues with greater MC-1R affinity and stability. Furthermore, peptide cyclization via disulfide and lactam bond formation as well as site-specific metal coordination resulted in additional gains in receptor affinity and peptide stability in vitro and in vivo. Radiochemical stability of the a-MSH analogues was improved through the conjugation of metal chelators to the peptide's N-terminus or lysine residues for radionuclide coordination. In vitro cell binding studies demonstrated that the radiolabeled a-MSH analogues had low to subnanomolar affinities for the MC1-R. Biodistribution and imaging studies in the B16 mouse melanoma modeled showed rapid tumor uptake of the radiolabeled peptides, with the cyclic peptides demonstrating prolonged tumor retention. Cyclic a-MSH analogues labeled with beta and alpha emitting radionuclides demonstrated melanoma therapeutic efficacy in the B16 melanoma mouse model. Strong pre-clinical imaging and therapy data highlight the clinical potential use of radiolabeled a-MSH peptides for melanoma imaging and treatment of disseminated disease.
Quinn
T
T
Biochemistry Department, University of Missouri, Harry S Truman Memorial Veterans Administration Hospital Columbia, MO 65211, USA. quinnt@missouri.edu
Zhang
X
X
Miao
Y
Y
D006801:Humans; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D044102:Receptor, Melanocortin, Type 1; D012878:Skin Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D015899:Tomography, Emission-Computed, Single-Photon; D000521:alpha-MSH / Q000031:analogs & derivatives*
D044102:Receptor, Melanocortin, Type 1; D000521:alpha-MSH
Radiat Res. 1998 Feb;149(2):155-62
9457895
Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84
14624632
J Nucl Med. 2004 Jan;45(1):116-23
14734683
J Nucl Med. 1994 Nov;35(11):1741-7
7965150
Bioconjug Chem. 1996 Mar-Apr;7(2):165-79
8983338
Acta Med Austriaca. 2002;29(5):162-70
12506767
J Nucl Med. 2000 Sep;41(9):1491-4
10994727
J Recept Res. 1988;8(1-4):323-43
2838620
J Med Chem. 1985 May;28(5):583-8
2985783
Cancer. 2005 Aug 1;104(3):570-9
15977211
J Recept Res. 1991;11(1-4):311-22
1653337
Bioconjug Chem. 1996 Mar-Apr;7(2):233-9
8983345
J Nucl Med. 2005 Dec;46(12):2097-103
16330576
Curr Med Chem. 2000 Sep;7(9):971-94
10911025
Int J Cancer. 2001 Jun 1;92(5):628-33
11340564
Science. 2001 Nov 16;294(5546):1537-40
11711678
Int J Cancer. 2002 Oct 10;101(5):480-7
12216078
J Nucl Med. 2007 Jan;48(1):73-80
17204701
Proc Natl Acad Sci U S A. 1980 Oct;77(10):5754-8
6777774
Bioconjug Chem. 2007 May-Jun;18(3):765-72
17348700
J Clin Invest. 1990 Jun;85(6):1825-32
2347915
J Med Chem. 1989 Dec;32(12):2555-61
2555512
Semin Nucl Med. 2002 Apr;32(2):133-40
11965608
Cancer Res. 2004 Feb 15;64(4):1411-8
14973076
J Nucl Med. 2004 Oct;45(10):1716-20
15471839
Arch Dermatol. 2004 Jul;140(7):827-35
15262693
J Med Chem. 2002 Jul 4;45(14):3048-56
12086490
Nucl Med Biol. 2008 Jan;35(1):91-9
18158948
CA Cancer J Clin. 2004 May-Jun;54(3):131-49; quiz 182-4
15195788
Recent Prog Horm Res. 1996;51:287-317; discussion 318
8701084
J Nucl Med. 2008 Mar;49(3):480-508
18287273
Br J Dermatol. 2004 Feb;150(2):179-85
14996086
Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):595-616
16183530
J Med Chem. 1980 Dec;23(12):1432-7
7452698
Science. 1992 Aug 28;257(5074):1248-51
1325670
Nucl Med Biol. 2007 Nov;34(8):945-53
17998097
Cancer Res. 1989 Nov 15;49(22):6352-8
2804981
Ann N Y Acad Sci. 1993 May 31;680:51-63
8390180
J Mol Recognit. 2003 Sep-Oct;16(5):248-54
14523936
J Natl Compr Canc Netw. 2009 Mar;7(3):281-9
19401061
J Nucl Med. 2007 Jan;48(1):64-72
17204700
Nature. 2007 Feb 22;445(7130):843-50
17314970
Acta Radiol. 2000 Sep;41(5):446-52
11016764
J Nucl Med. 2008 May;49(5):823-9
18413404
Eur J Nucl Med. 1997 Jul;24(7):792-5
9211767
Cancer Res. 1990 Feb 1;50(3 Suppl):904s-908s
2297740
Peptides. 1990 Mar-Apr;11(2):351-7
2162535
Cancer Res. 2000 Oct 15;60(20):5649-58
11059756
Nucl Med Biol. 2009 Apr;36(3):267-76
19324272
Nature. 1961 Jan 21;189:176-9
13761067
Br J Radiol. 1992 Feb;65(770):112-8
1540800
Br J Cancer. 1990 Dec;62(6):919-22
2257220
J Nucl Med. 2004 Aug;45(8):1323-7
15299056
Clin Cancer Res. 2005 Aug 1;11(15):5616-21
16061880
Chem Rev. 2001 Jul;101(7):2019-36
11710239
Adv Drug Deliv Rev. 2008 Sep;60(12):1347-70
18538888
Nucl Med Biol. 1999 Aug;26(6):687-93
10587108
J Nucl Med. 2001 Feb;42(2):248-56
11216523
J Nucl Med. 2003 Oct;44(10):1561-5
14530467
Arch Surg. 1992 Apr;127(4):392-9
1558490
Int J Pept Protein Res. 1981 Apr;17(4):514-8
7309356
Life Sci. 1984 Mar 5;34(10):977-84
6608041
J Biol Inorg Chem. 2008 Mar;13(3):449-59
18183429
Dalton Trans. 2007 Nov 21;(43):4918-28
17992276
J Clin Oncol. 2001 May 15;19(10):2674-8
11352959
Curr Pharm Des. 2008;14(24):2385-400
18781989
J Nucl Med. 2005 Jan;46(1):121-9
15632042
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8
9788997
Nucl Med Biol. 2005 Jul;32(5):485-93
15982579
J Nucl Med. 1991 Jan;32(1):174-85
1988628
Br J Cancer. 2002 Jul 15;87(2):151-7
12107834
Nucl Med Biol. 1997 Feb;24(2):171-8
9089709
Lancet. 1998 Feb 7;351(9100):417-8
9482300
J Nucl Med. 1989 Jan;30(1):25-32
2642954
Mol Imaging Biol. 2007 Jan-Feb;9(1):50-7
17051322
Int J Biochem Cell Biol. 1996 Nov;28(11):1223-32
9022281
J Nucl Med. 2001 Dec;42(12):1847-55
11752084
Bioconjug Chem. 2008 Feb;19(2):539-47
18197608
Bioconjug Chem. 2009 Aug 19;20(8):1634-42
19552406
Cancer. 2001 Apr 15;91(8):1530-42
11301402
Peptides. 1996;17(6):995-1002
8899819
Nucl Med Biol. 2009 Jul;36(5):505-13
19520291
J Nucl Med. 2009 Oct;50(10):1692-9
19759116
Cancer Biother Radiopharm. 2007 Jun;22(3):333-41
17651039
Int J Rad Appl Instrum A. 1988;39(4):283-6
2838433
J Med Chem. 2005 Apr 21;48(8):2985-92
15828837
J Urol. 1998 Aug;160(2):389-93
9679884
J Nucl Med. 2002 Dec;43(12):1699-706
12468522
Bioconjug Chem. 1997 May-Jun;8(3):347-53
9177840
Melanoma Res. 2008 Feb;18(1):56-60
18227709
Eur J Nucl Med. 1991;18(6):408-31
1879447
J Nucl Med. 2002 Jun;43(6):811-27
12050328
J Nucl Med. 2009 Nov;50(11):1865-72
19837749
Cell Mol Life Sci. 2001 Mar;58(3):434-41
11315190
J Nucl Med. 2007 Jun;48(6):987-94
17504880
Ann N Y Acad Sci. 1993 May 31;680:652-4
8390210
Curr Med Chem. 2009;16(17):2086-94
19519383